サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1736412

線維筋痛症治療の世界市場規模：薬剤クラス別、治療別、エンドユーザー別、地域範囲別および予測

Global Fibromyalgia Treatment Market Size By Drug Class, By Treatment, By End-Users, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
線維筋痛症治療の世界市場規模：薬剤クラス別、治療別、エンドユーザー別、地域範囲別および予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

線維筋痛症治療の市場規模と予測

線維筋痛症治療市場規模は、2024年に18億1,176万米ドルと評価され、2026～2032年にかけて4.15%のCAGRで成長し、2032年には25億828万米ドルに達すると予測されます。

  • 線維筋痛症治療とは、広範な筋骨格系の疼痛、疲労、認知障害を特徴とする慢性疾患である線維筋痛症の症状を管理するために考案された一連の医療療法、薬剤療法、その他の解決策を指します。
  • これは主に、病院、クリニック、薬局などのヘルスケアプロバイダが、線維筋痛症に苦しむ患者を治療するために利用しています。
  • 線維筋痛症の管理には、疼痛緩和薬、抗うつ薬、抗痙攣薬などの疼痛管理、理学療法、カウンセリングなどが一般的に用いられます。
  • 線維筋痛症の症状を緩和し、疼痛を軽減し、睡眠障害やうつ病などの関連疾患を管理することで、線維筋痛症患者の生活の質を向上させるために用いられます。
  • 線維筋痛症に対する理解が深まるにつれ、この慢性的でしばしば衰弱する症状からの解放を求める患者数の増加に対応し、新たな治療選択肢を提供することで市場は拡大しています。
  • 線維筋痛症は、全身の痛み、疲労、睡眠、記憶、気分の障害を引き起こす長期的な疾患です。
  • 線維筋痛症は慢性的な疾患であり、様々な症状を伴うため、治療は病気を治すことよりもむしろ、症状を管理することに主眼が置かれています。

線維筋痛症治療の世界市場力学

世界の線維筋痛症治療市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

  • 線維筋痛症の有病率の増加：世界的に線維筋痛症と診断される患者数が増加しており、効果的な治療オプションに対する需要が高まっている
  • 疾患に対する認識の高まり：認知度の向上と診断方法の改善により、治療を希望する患者が増加しています。
  • 医薬品開発の進歩：米国国立衛生ラボ（NIH）の報告によると、線維筋痛症研究のための資金は2019年の1,300万米ドルから2023年には1,800万米ドルへと38%増加しました。FDAによると、現在、線維筋痛症治療に特化した臨床検査が25以上あり、様々な段階にあります。製薬会社は線維筋痛症に対するより効果的な新薬の開発に注力しており、市場成長を牽引しています。
  • ヘルスケアインフラの改善：特に発展途上地域におけるヘルスケア施設の開発により、線維筋痛症治療へのアクセスが増加しています。
  • 非医薬品療法に対する需要の高まり：認知行動療法（CBT）や身体リハビリテーションのような代替療法への嗜好の高まりが市場成長を後押ししています。

主要市場課題

  • 診断の難しさ：線維筋痛症は他の疾患と症状が重複するため診断が難しく、タイムリーな治療の妨げとなります。
  • 開発途上地域における認知度の低さ：特定の地域における認知度や診断ツールの不足が、市場の可能性を制限しています。
  • 既存薬の副作用：多くの線維筋痛症治療には重大な副作用があり、患者の服薬アドヒアランスと市場成長に影響を及ぼします。
  • 高い治療費：特に低所得者層では、薬や治療にかかる費用がアクセスを制限する可能性があります。
  • 治療法の欠如：永続的な治療法がないため、市場は対症療法に限定され、長期的な効果は限定的です。

主要市場動向

  • 個別化医療の開発：個別化治療への注目が高まり、線維筋痛症市場の牽引役となっています。
  • 遠隔医療の統合：遠隔医療プラットフォームが普及し、患者は診察やフォローアップを受けやすくなっています。
  • 非医薬品治療の成長：マインドフルネス、鍼治療、運動プログラムなどの代替療法を選択する患者が増加しています。
  • 併用療法：より包括的な治療のために、医薬品と非医薬品治療を組み合わせる傾向が強まっています。
  • 生物製剤の調査：線維筋痛症の症状の根本的な原因を対象とした生物製剤や新規療法に関する新たな研究が行われており、将来的にはより効果的な解決策が期待されています。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査スケジュール
  • 前提条件
  • 限界

第2章 調査手法

  • データマイニング
  • 二次調査
  • 一次調査
  • 専門家の助言
  • クオリティチェック
  • 最終レビュー
  • データの三角測量
  • ボトムアップアプローチ
  • トップダウンアプローチ
  • 調査の流れ
  • データソース

第3章 エグゼクティブサマリー

  • 世界の線維筋痛症治療市場概要
  • 線維筋痛症治療の世界生態マッピング
  • 線維筋痛症治療の世界絶対的収益機会
  • 線維筋痛症治療の世界市場の魅力（地域別）
  • 線維筋痛症治療の地域の市場分析
  • 線維筋痛症治療の世界市場：流通チャネル別
  • 線維筋痛症治療世界市場：薬剤クラス別
  • 今後の市場機会
  • 世界市場内訳

第4章 市場展望

  • 線維筋痛症治療の世界市場展望
  • 市場の進化
  • 市場促進要因
    • 新規線維筋痛症治療の承認と上市
    • 強力な製品パイプラインと線維筋痛症の増加
  • 抑制要因
    • 線維筋痛症治療の副作用
    • 適応外薬やジェネリック医薬品の採用増加
  • 可能性
    • 線維筋痛症治療のための新しい治療法開発のための研究開発活動の増加
  • 世界の線維筋痛症治療市場に及ぼすCOVID-19の影響
  • マクロ経済分析
  • ポーターのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 供給企業の交渉力
    • 買い手の交渉力
    • 競争企業間の敵対関係
  • 価格分析

第5章 薬剤クラス別市場

  • 概要
  • 抗うつ薬
  • 抗けいれん薬
  • 麻酔薬
  • 筋弛緩薬

第6章 治療別市場

  • 概要
  • 治療
  • 治療
  • ライフスタイルの変化

第7章 エンドユーザー別市場

  • 概要
  • 病院
  • クリニック

第8章 地域別市場

  • 概要
  • 北米
    • 北米市場スナップショット
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州市場スナップショット
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • アジア太平洋市場スナップショット
    • 中国
    • インド
    • 日本
    • その他のアジア太平洋
  • ラテンアメリカ
    • ラテンアメリカ市場スナップショット
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • 中東・アフリカ市場スナップショット
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他の中東・アフリカ

第9章 競合情勢

  • 概要
  • 企業の市場ランキング分析
  • 地域別フットプリント
  • 企業の産業別フットプリント
  • エースマトリックス
    • アクティブ
    • カッティングエッジ
    • エマージング
    • イノベーター

第10章 企業プロファイル

  • PFIZER
  • INNOVATIVE MED CONCEPTS
  • NOVARTIS AG
  • ELI LILLY & COMPANY
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • INTEC PHARMA LTD.
  • ABBVIE
  • FSD PHARMA
  • MERCK & CO.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

LIST OF TABLES

  • TABLE1 PROJECTED REAL GDP GROWTH (ANNUAL PERCENTAGE CHANGE) OF KEY COUNTRIES
  • TABLE 2 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 3 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 4 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
  • TABLE 5 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 6 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 7 NORTH AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 8 U.S. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 9 U.S. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE10 CANADA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE11 CANADA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE12 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE13 MEXICO FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE14 EUROPE FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE15 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE16 EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE17 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE18 GERMANY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE19 U.K. FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 20 U.K. FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 21 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 22 FRANCE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 23 ITALY FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 24 ITALY FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 25 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 26 SPAIN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 27 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 28 REST OF EUROPE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 29 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 31 ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 32 CHINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 33 CHINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 34 INDIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 35 INDIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 36 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 37 JAPAN FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS 2022-2030 (USD MILLION)
  • TABLE 38 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 39 REST OF ASIA PACIFIC FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 41 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 43 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 44 BRAZIL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 45 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 46 ARGENTINA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 47 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 48 REST OF LATIN AMERICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 49 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 51 MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 52 UAE FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 53 UAE FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 54 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 55 SAUDI ARABIA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 56 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 57 SOUTH AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 58 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2030 (USD MILLION)
  • TABLE 59 REST OF MIDDLE EAST AND AFRICA FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS, 2022-2030 (USD MILLION)
  • TABLE 60 COMPANY MARKET RANKING ANALYSIS
  • TABLE 61 COMPANY REGIONAL FOOTPRINT
  • TABLE 62 COMPANY INDUSTRY FOOTPRINT
  • TABLE 63 PFIZER INC.: PRODUCT BENCHMARKING
  • TABLE 64 PFIZER INC.: WINNING IMPERATIVES
  • TABLE 65 NOVARTIS AG: PRODUCT BENCHMARKING
  • TABLE 66 NOVARTIS AG: WINNING IMPERATIVES
  • TABLE 67 ABBVIE: PRODUCT BENCHMARKING
  • TABLE 68 ABBVIE: KEY DEVELOPMENTS
  • TABLE 69 ABBVIE: WINNING IMPERATIVES
  • TABLE 70 ELI LILLY AND COMPANY: PRODUCT BENCHMARKING
  • TABLE 71 VIRIOS THERAPEUTICS, INC.: PRODUCT BENCHMARKING
  • TABLE 72 VIRIOS THERAPEUTICS, INC.: KEY DEVELOPMENTS
  • TABLE 73 ASTELLAS PHARMA: PRODUCT BENCHMARKING
  • TABLE 74 ASTELLAS PHARMA: KEY DEVELOPMENTS
  • TABLE 75 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT BENCHMARKING
  • TABLE 76 INTEC PHARMA S.R.O.: PRODUCT BENCHMARKING
  • TABLE 77 APTINYX INC.: PRODUCT BENCHMARKING
  • TABLE 78 APTINYX INC.: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE1 GLOBAL FIBROMYALGIA TREATMENT MARKET SEGMENTATION
  • FIGURE 2 RESEARCH TIMELINES
  • FIGURE 3 DATA TRIANGULATION
  • FIGURE 4 MARKET RESEARCH FLOW
  • FIGURE 5 DATA SOURCES
  • FIGURE 6 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS, 2023-30
  • FIGURE 7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
  • FIGURE 8 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
  • FIGURE 9 FUTURE MARKET OPPORTUNITIES
  • FIGURE10 NORTH AMERICA DOMINATED THE MARKET IN 2021
  • FIGURE11 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
  • FIGURE12 PORTER'S FIVE FORCES ANALYSIS FOR GLOBAL FIBROMYALGIA TREATMENT MARKET
  • FIGURE13 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
  • FIGURE14 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS
  • FIGURE15 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY GEOGRAPHY, 2022-2030 (USD MILLION)
  • FIGURE16 U.S. MARKET SNAPSHOT
  • FIGURE17 CANADA MARKET SNAPSHOT
  • FIGURE18 MEXICO MARKET SNAPSHOT
  • FIGURE19 GERMANY MARKET SNAPSHOT
  • FIGURE 20 U.K. MARKET SNAPSHOT
  • FIGURE 21 FRANCE MARKET SNAPSHOT
  • FIGURE 22 ITALY MARKET SNAPSHOT
  • FIGURE 23 SPAIN MARKET SNAPSHOT
  • FIGURE 24 REST OF EUROPE MARKET SNAPSHOT
  • FIGURE 25 CHINA MARKET SNAPSHOT
  • FIGURE 26 INDIA MARKET SNAPSHOT
  • FIGURE 27 JAPAN MARKET SNAPSHOT
  • FIGURE 28 REST OF ASIA PACIFIC MARKET SNAPSHOT
  • FIGURE 29 BRAZIL MARKET SNAPSHOT
  • FIGURE 30 ARGENTINA MARKET SNAPSHOT
  • FIGURE 31 REST OF LATIN AMERICA MARKET SNAPSHOT
  • FIGURE 32 UAE MARKET SNAPSHOT
  • FIGURE 33 SAUDI ARABIA MARKET SNAPSHOT
  • FIGURE 34 SOUTH AFRICA MARKET SNAPSHOT
  • FIGURE 35 REST OF MIDDLE EAST AND AFRICA MARKET SNAPSHOT
  • FIGURE 36 KEY STRATEGIC DEVELOPMENTS
  • FIGURE 37 ACE MATRIX
  • FIGURE 38 PFIZER INC.: COMPANY INSIGHT
  • FIGURE1 PFIZER INC.: SEGMENT BREAKDOWN
  • FIGURE 2 PFIZER INC.: SWOT ANALYSIS
  • FIGURE 3 NOVARTIS AG: COMPANY INSIGHT
  • FIGURE 4 NOVARTIS AG: BREAKDOWN
  • FIGURE 5 NOVARTIS AG: SWOT ANALYSIS
  • FIGURE 6 ABBVIE: COMPANY INSIGHT
  • FIGURE 7 ABBVIE: SEGMENT BREAKDOWN
  • FIGURE 8 ABBVIE: SWOT ANALYSIS
  • FIGURE 9 ELI LILLY AND COMPANY: COMPANY INSIGHT
  • FIGURE10 ELI LILLY AND COMPANY: BREAKDOWN
  • FIGURE11 VIRIOS THERAPEUTICS, INC.: COMPANY INSIGHT
  • FIGURE12 ASTELLAS PHARMA: COMPANY INSIGHT
  • FIGURE13 ASTELLAS PHARMA: SEGMENT BREAKDOWN
  • FIGURE14 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY INSIGHT
  • FIGURE15 SUN PHARMACEUTICAL INDUSTRIES LTD.: SEGMENT BREAKDOWN
  • FIGURE16 INTEC PHARMA S.R.O.: COMPANY INSIGHT
  • FIGURE17 APTINYX INC.: COMPANY INSIGHT
  • FIGURE18 PRISMIC PHARMACEUTICALS: COMPANY INSIGHT
  • FIGURE19 PRISMIC PHARMACEUTICALS: PRODUCT BENCHMARKING
目次
Product Code: 36116

Fibromyalgia Treatment Market Size And Forecast

Fibromyalgia Treatment Market size was valued at USD 1811.76 Million in 2024 and is projected to reach USD 2508.28 Million by 2032, growing at a CAGR of 4.15% from 2026 to 2032.

  • Fibromyalgia treatment refers to the range of medical therapies, medications, and other solutions designed to manage the symptoms of fibromyalgia, a chronic condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties.
  • This is primarily utilized by healthcare providers, including hospitals, clinics, and pharmacies, to treat patients suffering from fibromyalgia.
  • Medications like pain relievers, antidepressants, and anti-seizure drugs, as well as physical therapy and counseling, are commonly used in fibromyalgia management.
  • It is used to improve the quality of life for fibromyalgia patients by alleviating symptoms, reducing pain, and managing associated conditions such as sleep disturbances and depression.
  • As the understanding of fibromyalgia improves, the market is expanding with new treatment options, catering to the growing number of patients seeking relief from this chronic, often debilitating condition.
  • Fibromyalgia is a long-term disorder that causes pain throughout the body, fatigue, and difficulties with sleep, memory, and mood.
  • Due to the chronic nature of the condition and the variety of symptoms associated with it, treatment is primarily focused on managing the symptoms rather than curing the disease.

Global Fibromyalgia Treatment Market Dynamics

The key market dynamics that are shaping the global fibromyalgia treatment market include:

Key Market Drivers

  • Increasing Prevalence of Fibromyalgia: The rising number of people diagnosed with fibromyalgia globally is driving demand for effective treatment options.
  • Growing Awareness of the Disorder: Enhanced public awareness and better diagnostic methods are leading to more individuals seeking treatment.
  • Advancements in Drug Development: The National Institutes of Health (NIH) reported funding for fibromyalgia research increased from $13 million in 2019 to $18 million in 2023, a 38% increase. According to the FDA, there are currently over 25 clinical trials specifically focused on fibromyalgia treatments in various phases. Pharmaceutical companies are focusing on the development of new and more effective drugs for fibromyalgia, driving market growth.
  • Improved Healthcare Infrastructure: Expanding healthcare facilities, especially in developing regions, is increasing access to fibromyalgia treatments.
  • Rising Demand for Non-Pharmaceutical Therapies: The growing preference for alternative therapies like cognitive behavioral therapy (CBT) and physical rehabilitation is boosting market growth.

Key Market Challenges:

  • Difficulty in Diagnosis: Fibromyalgia can be difficult to diagnose due to overlapping symptoms with other conditions, hindering timely treatment.
  • Limited Awareness in Developing Regions: Lack of awareness and diagnostic tools in certain regions limits the market potential.
  • Side Effects of Existing Medications: Many fibromyalgia drugs have significant side effects, affecting patient adherence and market growth.
  • High Treatment Costs: The expense of medications and therapies can limit access, particularly in low-income areas.
  • Lack of Curative Treatment: The absence of a permanent cure restricts the market to symptom management, limiting long-term effectiveness.

Key Market Trends:

  • Development of Personalized Medicine: The increasing focus on personalized treatment approaches is gaining traction in the fibromyalgia market.
  • Integration of Telemedicine: Telemedicine platforms are becoming more prevalent, allowing patients easier access to consultations and follow-ups.
  • Non-Pharmaceutical Treatment Growth: More patients are opting for alternative therapies such as mindfulness, acupuncture, and exercise programs.
  • Combination Therapies: There is a growing trend toward combining pharmaceutical and non-pharmaceutical treatments for more comprehensive care.
  • Research in Biologics: New research is being conducted into biologics and novel therapies that target the root causes of fibromyalgia symptoms, promising more effective solutions in the future.

Global Fibromyalgia Treatment Market Regional Analysis

Here is a more detailed regional analysis of the fibromyalgia treatment market:

North America

  • The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure.
  • According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population.
  • The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases.
  • The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.
  • The presence of key pharmaceutical companies focused on developing innovative therapies for fibromyalgia further strengthens the region's market position.
  • Growing research and development activities aimed at discovering new drugs and treatment modalities have fueled market expansion.
  • Government initiatives and healthcare programs in the U.S. and Canada to promote awareness and provide access to treatment for chronic pain conditions have played a crucial role in market growth.
  • The rising demand for personalized medicine and alternative therapies such as cognitive behavioral therapy (CBT), physiotherapy, and mindfulness practices is also influencing the market dynamics in North America.
  • The high cost of treatment and the side effects associated with some medications remain key challenges in the region.
  • Despite this, North America's dominant healthcare infrastructure and ongoing advancements in fibromyalgia treatment continue to drive market growth.

Asia Pacific

  • The Asia Pacific region is anticipated to witness the fastest growth in the Global Fibromyalgia Treatment Market, driven by increasing awareness of chronic pain conditions and improving healthcare infrastructure.
  • Countries such as China, Japan, India, and South Korea are contributing to market expansion as healthcare access becomes more widespread and diagnosis rates for fibromyalgia improve.
  • The region's growing aging population is also a key factor, as fibromyalgia tends to affect older adults more frequently.
  • Rising healthcare expenditure and the availability of affordable treatment options are facilitating the market's growth in Asia Pacific.
  • Governments in countries like India and China are initiating healthcare reforms aimed at increasing the accessibility of pain management therapies, which is positively impacting the fibromyalgia treatment market.
  • Despite these advancements, challenges such as low awareness in rural areas and limited availability of specialized treatment centers pose obstacles to market growth.
  • The increasing focus on research and development, along with the growing demand for non-invasive treatments and alternative therapies like acupuncture and herbal medicines, is expected to drive continued growth in the Asia Pacific fibromyalgia treatment market in the coming years.

Global Fibromyalgia Treatment Market: Segmentation Analysis

The Global Fibromyalgia Treatment Market is segmented based on Drug Class, Treatment, End-Users, and Geography.

Fibromyalgia Treatment Market, By Drug Class

  • Antidepressants
  • Anticonvulsants
  • Analgesics
  • Muscle Relaxants

Based on drug class, the Global Fibromyalgia Treatment Market is segmented into Antidepressants, Anticonvulsants, Analgesics, and Muscle Relaxants. The Antidepressant segment significantly dominates the Global Fibromyalgia Treatment Market owing to their effectiveness in reducing pain and improving mood in fibromyalgia patients.

Fibromyalgia Treatment Market, By Treatment

  • Medication
  • Therapy
  • Lifestyle Changes

Based on treatment, the Global Fibromyalgia Treatment Market is segmented into Medication, Therapy, and Lifestyle Changes. The Medication segment significantly dominates the Global Fibromyalgia Treatment Market owing to its central role in symptom management, with drugs like antidepressants and pain relievers commonly prescribed.

Fibromyalgia Treatment Market, By End-Users

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Online Pharmacies

Based on end-users, the Global Fibromyalgia Treatment Market is segmented into Hospitals, Clinics, Retail Pharmacies, and Online Pharmacies. Hospitals significantly dominate the Global Fibromyalgia Treatment Market owing to the availability of specialized care and advanced treatment options for fibromyalgia patients.

Fibromyalgia Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the global fibromyalgia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region significantly dominates the Global Fibromyalgia Treatment Market owing to the rising prevalence of fibromyalgia and a well-established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), fibromyalgia affects about 4 million US adults, approximately 2% of the adult population. The National Fibromyalgia Association reports that the condition is more prevalent in women, with females accounting for 75-90% of cases. The U.S. leads the market, driven by increased diagnosis rates, greater public awareness of the condition, and the availability of advanced treatment options.

Key Players

The "Global Fibromyalgia Treatment Market" study report provides valuable insight with an emphasis on the global market. The major players in the market are Fizer, Innovative Med Concepts, Novartis AG, Eli Lilly & Company, Sun Pharmaceutical Industries Ltd., Intec Pharma Ltd., AbbVie, FSD Pharma, Merck & Co., Teva Pharmaceutical Industries Ltd., Lupin Limited, Viatris Inc., Tonix Pharmaceuticals Holding Corp., and Aptinyx Inc.

  • This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Fibromyalgia Treatment Market Key Developments

  • In August 2022, Aptinyx Inc. announced the results from a Phase 2b clinical study that evaluated the effects of NYX-2925 in patients with fibromyalgia. The study revealed that NYX-2925 did not achieve statistically significant separation from placebo on the primary endpoint, which measured the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
  • In October 2020, Eli Lily announced a collaboration with Daiichi Sankyo in Japan for the commercialization of Galcanezumab, an anti-CGRP antibody potentially used to treat migraines. Under this agreement, Daiichi Sankyo was responsible for the sales and distribution of Galcanezumab, while Eli Lily Japan retained the marketing license, pending marketing approval.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 MARKET DEFINITION
  • 1.2 MARKET SEGMENTATION
  • 1.3 RESEARCH TIMELINES
  • 1.4 ASSUMPTIONS
  • 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 DATA MINING
  • 2.2 SECONDARY RESEARCH
  • 2.3 PRIMARY RESEARCH
  • 2.4 SUBJECT MATTER EXPERT ADVICE
  • 2.5 QUALITY CHECK
  • 2.6 FINAL REVIEW
  • 2.7 DATA TRIANGULATION
  • 2.8 BOTTOM-UP APPROACH
  • 2.9 TOP-DOWN APPROACH
  • 2.10 RESEARCH FLOW
  • 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

  • 3.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OVERVIEW
  • 3.2 GLOBAL FIBROMYALGIA TREATMENT ECOLOGY MAPPING
  • 3.3 GLOBAL FIBROMYALGIA TREATMENT ABSOLUTE MARKET OPPORTUNITY
  • 3.4 GLOBAL FIBROMYALGIA TREATMENT MARKET ATTRACTIVENESS, BY REGION
  • 3.5 GLOBAL FIBROMYALGIA TREATMENT MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
  • 3.6 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL (USD MILLION)
  • 3.7 GLOBAL FIBROMYALGIA TREATMENT MARKET, BY DRUG CLASS (USD MILLION)
  • 3.8 FUTURE MARKET OPPORTUNITIES
  • 3.9 GLOBAL MARKET SPLIT

4 MARKET OUTLOOK

  • 4.1 GLOBAL FIBROMYALGIA TREATMENT MARKET OUTLOOK
  • 4.2 MARKET EVOLUTION
  • 4.3 MARKET DRIVERS
    • 4.3.1 APPROVAL AND LAUNCH OF NOVEL FIBROMYALGIA TREATMENT DRUGS
    • 4.3.2 STRONG PRODUCT PIPELINE AND INCREASING OCCURRENCE OF FIBROMYALGIA
  • 4.4 RESTRAINTS
    • 4.4.1 SIDE EFFECTS OF THE DRUGS USED FOR THE TREATMENT OF FIBROMYALGIA
    • 4.4.2 HIGHER ADOPTION OF OFF-LABEL AND GENERIC DRUGS
  • 4.5 OPPORTUNITIES
    • 4.5.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NEW THERAPIES FOR THE TREATMENT OF FIBROMYALGIA
  • 4.6 IMPACT OF COVID19 ON GLOBAL FIBROMYALGIA TREATMENT MARKET
  • 4.7 MACROECONOMIC ANALYSIS
  • 4.8 PORTER'S FIVE FORCES ANALYSIS
    • 4.8.1 THREAT OF NEW ENTRANTS
    • 4.8.2 THREAT OF SUBSTITUTES
    • 4.8.3 BARGAINING POWER OF SUPPLIERS
    • 4.8.4 BARGAINING POWER OF BUYERS
    • 4.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 4.9 PRICING ANALYSIS

5 MARKET, BY DRUG CLASS

  • 5.1 OVERVIEW
  • 5.2 ANTIDEPRESSANTS
  • 5.3 ANTICONVULSANTS
  • 5.4 ANALGESICS
  • 5.5 MUSCLE RELAXANTS

6 MARKET, BY TREATMENT

  • 6.1 OVERVIEW
  • 6.2 MEDICATION
  • 6.3 THERAPY
  • 6.4 LIFESTYLE CHANGES

7 MARKET, BY END-USERS

  • 7.1 OVERVIEW
  • 7.2 HOSPITALS
  • 7.2 CLINICS

8 MARKET, BY GEOGRAPHY

  • 8.1 OVERVIEW
  • 8.2 NORTH AMERICA
    • 8.2.1 NORTH AMERICA MARKET SNAPSHOT
    • 8.2.2 U.S.
    • 8.2.3 CANADA
    • 8.2.4 MEXICO
  • 8.3 EUROPE
    • 8.3.1 EUROPE MARKET SNAPSHOT
    • 8.3.2 GERMANY
    • 8.3.3 U.K.
    • 8.3.4 FRANCE
    • 8.3.5 ITALY
    • 8.3.6 SPAIN
    • 8.3.7 REST OF EUROPE
  • 8.4 ASIA PACIFIC
    • 8.4.1 ASIA PACIFIC MARKET SNAPSHOT
    • 8.4.2 CHINA
    • 8.4.3 INDIA
    • 8.4.4 JAPAN
    • 8.4.5 REST OF ASIA PACIFIC
  • 8.5 LATIN AMERICA
    • 8.5.1 LATIN AMERICA MARKET SNAPSHOT
    • 8.5.2 BRAZIL
    • 8.5.3 ARGENTINA
    • 8.5.4 REST OF LATIN AMERICA
  • 8.6 MIDDLE EAST AND AFRICA
    • 8.6.1 MIDDLE EAST AND AFRICA MARKET SNAPSHOT
    • 8.6.2 UAE
    • 8.6.3 SAUDI ARABIA
    • 8.6.4 SOUTH AFRICA
    • 8.6.5 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 COMPANY MARKET RANKING ANALYSIS,
  • 9.3 COMPANY REGIONAL FOOTPRINT
  • 9.4 COMPANY INDUSTRY FOOTPRINT
  • 9.5 ACE MATRIX
    • 9.5.1 ACTIVE
    • 9.5.2 CUTTING EDGE
    • 9.5.3 EMERGING
    • 9.5.4 INNOVATORS

10 COMPANY PROFILES

  • 10.1 PFIZER
    • 10.1.1 COMPANY OVERVIEW
    • 10.1.2 COMPANY INSIGHTS
    • 10.1.3 SEGMENT BREAKDOWN
    • 10.1.4 PRODUCT BENCHMARKING
    • 10.1.5 KEY DEVELOPMENTS
    • 10.1.6 WINNING IMPERATIVES
    • 10.1.7 CURRENT FOCUS & STRATEGIES
    • 10.1.8 THREAT FROM COMPETITION
    • 10.1.9 SWOT ANALYSIS
  • 10.2 INNOVATIVE MED CONCEPTS
    • 10.2.1 COMPANY OVERVIEW
    • 10.2.2 COMPANY INSIGHTS
    • 10.2.3 SEGMENT BREAKDOWN
    • 10.2.4 PRODUCT BENCHMARKING
    • 10.2.5 KEY DEVELOPMENTS
    • 10.2.6 WINNING IMPERATIVES
    • 10.2.7 CURRENT FOCUS & STRATEGIES
    • 10.2.8 THREAT FROM COMPETITION
    • 10.2.9 SWOT ANALYSIS
  • 10.3 NOVARTIS AG
    • 10.3.1 COMPANY OVERVIEW
    • 10.3.2 COMPANY INSIGHTS
    • 10.3.3 SEGMENT BREAKDOWN
    • 10.3.4 PRODUCT BENCHMARKING
    • 10.3.5 KEY DEVELOPMENTS
    • 10.3.6 WINNING IMPERATIVES
    • 10.3.7 CURRENT FOCUS & STRATEGIES
    • 10.3.8 THREAT FROM COMPETITION
    • 10.3.9 SWOT ANALYSIS
  • 10.4 ELI LILLY & COMPANY
    • 10.4.1 COMPANY OVERVIEW
    • 10.4.2 COMPANY INSIGHTS
    • 10.4.3 SEGMENT BREAKDOWN
    • 10.4.4 PRODUCT BENCHMARKING
    • 10.4.5 KEY DEVELOPMENTS
    • 10.4.6 WINNING IMPERATIVES
    • 10.4.7 CURRENT FOCUS & STRATEGIES
    • 10.4.8 THREAT FROM COMPETITION
    • 10.4.9 SWOT ANALYSIS
  • 10.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 10.5.1 COMPANY OVERVIEW
    • 10.5.2 COMPANY INSIGHTS
    • 10.5.3 SEGMENT BREAKDOWN
    • 10.5.4 PRODUCT BENCHMARKING
    • 10.5.5 KEY DEVELOPMENTS
    • 10.5.6 WINNING IMPERATIVES
    • 10.5.7 CURRENT FOCUS & STRATEGIES
    • 10.5.8 THREAT FROM COMPETITION
    • 10.5.9 SWOT ANALYSIS
  • 10.6 INTEC PHARMA LTD.
    • 10.6.1 COMPANY OVERVIEW
    • 10.6.2 COMPANY INSIGHTS
    • 10.6.3 SEGMENT BREAKDOWN
    • 10.6.4 PRODUCT BENCHMARKING
    • 10.6.5 KEY DEVELOPMENTS
    • 10.6.6 WINNING IMPERATIVES
    • 10.6.7 CURRENT FOCUS & STRATEGIES
    • 10.6.8 THREAT FROM COMPETITION
    • 10.6.9 SWOT ANALYSIS
  • 10.7 ABBVIE
    • 10.7.1 COMPANY OVERVIEW
    • 10.7.2 COMPANY INSIGHTS
    • 10.7.3 SEGMENT BREAKDOWN
    • 10.7.4 PRODUCT BENCHMARKING
    • 10.7.5 KEY DEVELOPMENTS
    • 10.7.6 WINNING IMPERATIVES
    • 10.7.7 CURRENT FOCUS & STRATEGIES
    • 10.7.8 THREAT FROM COMPETITION
    • 10.7.9 SWOT ANALYSIS
  • 10.8 FSD PHARMA
    • 10.8.1 COMPANY OVERVIEW
    • 10.8.2 COMPANY INSIGHTS
    • 10.8.3 SEGMENT BREAKDOWN
    • 10.8.4 PRODUCT BENCHMARKING
    • 10.8.5 KEY DEVELOPMENTS
    • 10.8.6 WINNING IMPERATIVES
    • 10.8.7 CURRENT FOCUS & STRATEGIES
    • 10.8.8 THREAT FROM COMPETITION
    • 10.8.9 SWOT ANALYSIS
  • 10.9 MERCK & CO.
    • 10.9.1 COMPANY OVERVIEW
    • 10.9.2 COMPANY INSIGHTS
    • 10.9.3 SEGMENT BREAKDOWN
    • 10.9.4 PRODUCT BENCHMARKING
    • 10.9.5 KEY DEVELOPMENTS
    • 10.9.6 WINNING IMPERATIVES
    • 10.9.7 CURRENT FOCUS & STRATEGIES
    • 10.9.8 THREAT FROM COMPETITION
    • 10.9.9 SWOT ANALYSIS
  • 10.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 10.10.1 COMPANY OVERVIEW
    • 10.10.2 COMPANY INSIGHTS
    • 10.10.3 SEGMENT BREAKDOWN
    • 10.10.4 PRODUCT BENCHMARKING
    • 10.10.5 KEY DEVELOPMENTS
    • 10.10.6 WINNING IMPERATIVES
    • 10.10.7 CURRENT FOCUS & STRATEGIES
    • 10.10.8 THREAT FROM COMPETITION
    • 10.10.9 SWOT ANALYSIS